von Moltke Lisa
Known title: DirectorCIK: 0001808592
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Tvardi releases preclinical data on STAT3 inhibitor for UC. Tvardi Therapeutics reported new preclinical results that show its STAT3 inhibitor may be effective in treating ulcerative colitis. The data were published in the International Journal of Molecular Sciences. The announcement appeared in recent market round‑ups of health‑care stocks moving in pre‑market and after‑hours sessions.
Transaction History
| MCRB | ▼ Sell | Open Market | 4,416 | $4K | 2/18/2025 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 2,969 | — | 2/15/2025 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 8,907 | — | 2/15/2025 | View on chart |
| MCRB | ▼ Sell | Open Market | 977 | $528 | 11/18/2024 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 2,969 | — | 11/15/2024 | View on chart |
| MCRB | ▼ Sell | Open Market | 4,334 | $3K | 10/28/2024 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 13,744 | $0 | 10/27/2024 | View on chart |
| MCRB | ▼ Sell | Open Market | 973 | $817 | 8/16/2024 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 2,969 | — | 8/15/2024 | View on chart |
| TVRD | ▲ Buy | Grant | 150,647 | $0 | 6/4/2024 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 2,968 | — | 5/15/2024 | View on chart |
| MCRB | ▼ Sell | Open Market | 939 | $883 | 5/15/2024 | View on chart |
| MCRB | ▼ Sell | Open Market | 4,400 | $5K | 2/16/2024 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 11,875 | — | 2/15/2024 | View on chart |
| MCRB | ▼ Sell | Open Market | 4,232 | $6K | 10/30/2023 | View on chart |
| MCRB | ▲ Buy | Option Exercise | 13,745 | $0 | 10/27/2023 | View on chart |
| TVRD | ▲ Buy | Grant | 32,362 | $0 | 6/1/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
MCRB to Present Preclinical Data on SER-428 at IDWeek 2026
Seres Therapeutics announced it will present preclinical data for SER-428, an investigational live biotherapeutic intended to reduce the risk of bloodstream infections in critically ill patients, at the upcoming IDWeek 2026 conference. The data will focus on early-stage results that support the development of the oral liquid LBP. The stock is currently trading near its $7.60 support level with an RSI of 22.8, indicating limited recent price momentum.
MCRB to Present Preclinical Data on SER-428 at IDWeek 2026. Seres Therapeutics announced it will present preclinical data for SER-428, an investigational live biotherapeutic intended to reduce the risk of bloodstream infections in critically ill patients, at the upcoming IDWeek 2026 conference. The data will focus on early-stage results that support the development of the oral liquid LBP. The stock is currently trading near its $7.60 support level with an RSI of 22.8, indicating limited recent price momentum.